Promising antitumor activity and safety of Ivonescimab in combination therapies in CRC, TNBC and HNSCC presented at ESMO 2024

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit”, “we” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, were presented at the European Society for Medical Oncology Annual Meeting (ESMO 2024) in Barcelona, ​​Spain, including two presentations and one poster detailing updated ivonescimab data in advanced triple-negative breast cancer (TNBC), recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic microsatellite-stable (MSS) colorectal cancer (CRC). Each study from which the data were generated was a Phase II study conducted in China and sponsored by Akeso Inc. (HKEX code: 9926.HK) with data generated and analyzed by Akeso.

Based on the results from these Phase II datasets and data previously announced in 2024, including early-stage non-small cell lung cancer and biliary tract cancer, Summit plans to explore further clinical development of ivonescimab in solid tumor settings outside of metastatic non-small cell lung cancer, the company’s current focus in its Phase III clinical trials.